+

WO1998025640A3 - Nouveaux procedes pour tester des inhibiteurs de filaments helicoidaux apparies et leur utilisation dans le traitement de la maladie d'alzheimer - Google Patents

Nouveaux procedes pour tester des inhibiteurs de filaments helicoidaux apparies et leur utilisation dans le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
WO1998025640A3
WO1998025640A3 PCT/EP1997/007007 EP9707007W WO9825640A3 WO 1998025640 A3 WO1998025640 A3 WO 1998025640A3 EP 9707007 W EP9707007 W EP 9707007W WO 9825640 A3 WO9825640 A3 WO 9825640A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
disease
treatment
paired helical
helical filaments
Prior art date
Application number
PCT/EP1997/007007
Other languages
English (en)
Other versions
WO1998025640A2 (fr
Inventor
Eckhard Mandelkow
Eva-Maria Mandelkow
Jacek Biernat
Peter Friedhoff
Original Assignee
Max Planck Gesellschaft
Eckhard Mandelkow
Mandelkow Eva Maria
Jacek Biernat
Peter Friedhoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Eckhard Mandelkow, Mandelkow Eva Maria, Jacek Biernat, Peter Friedhoff filed Critical Max Planck Gesellschaft
Priority to EP97953806A priority Critical patent/EP1019069A2/fr
Priority to JP52624598A priority patent/JP2001506617A/ja
Priority to AU57575/98A priority patent/AU5757598A/en
Publication of WO1998025640A2 publication Critical patent/WO1998025640A2/fr
Publication of WO1998025640A3 publication Critical patent/WO1998025640A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur l'utilisation d'inhibiteurs de polyanions intracellulaires, tels que des inhibiteurs d'ARN, de poly-Glu ou de polypeptides polyanioniques (tubuline ou ses parties) ou leurs dérivés (polycations ou ribozyme, par exemple), pour la prévention ou le traitement de la maladie d'Alzheimer. La présente invention porte en outre sur des procédés permettant de tester ces inhibiteurs pour déterminer leur capacité d'inhiber la formation de filaments hélicoïdaux appariés, et sur des trousses convenant à la réalisation de ces procédés.
PCT/EP1997/007007 1996-12-13 1997-12-12 Nouveaux procedes pour tester des inhibiteurs de filaments helicoidaux apparies et leur utilisation dans le traitement de la maladie d'alzheimer WO1998025640A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97953806A EP1019069A2 (fr) 1996-12-13 1997-12-12 Nouveaux procedes pour tester des inhibiteurs de filaments helicoidaux apparies et leur utilisation dans le traitement de la maladie d'alzheimer
JP52624598A JP2001506617A (ja) 1996-12-13 1997-12-12 ペアードヘリカルフィラメントの阻害剤を試験するための新規な方法およびアルツハイマー病治療のための使用
AU57575/98A AU5757598A (en) 1996-12-13 1997-12-12 Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96120120.9 1996-12-13
EP96120120 1996-12-13

Publications (2)

Publication Number Publication Date
WO1998025640A2 WO1998025640A2 (fr) 1998-06-18
WO1998025640A3 true WO1998025640A3 (fr) 1998-08-27

Family

ID=8223499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/007007 WO1998025640A2 (fr) 1996-12-13 1997-12-12 Nouveaux procedes pour tester des inhibiteurs de filaments helicoidaux apparies et leur utilisation dans le traitement de la maladie d'alzheimer

Country Status (5)

Country Link
US (1) US20020197737A1 (fr)
EP (1) EP1019069A2 (fr)
JP (1) JP2001506617A (fr)
AU (1) AU5757598A (fr)
WO (1) WO1998025640A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005543A1 (en) * 2002-01-18 2004-01-08 Abraham Grossman Compositions and methods for binding agglomeration proteins
US20050261486A1 (en) * 2001-05-31 2005-11-24 Q-Rna Compositions and methods for binding agglomeration proteins
US7172875B2 (en) * 2003-02-18 2007-02-06 The Ohio State University Research Foundation Identifying inhibitors of intracellular protein fibrillization
US11249093B2 (en) 2017-03-28 2022-02-15 Janssen Vaccines & Prevention B.V. Methods for detection of Tau protein aggregation modulating compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044669A1 (fr) * 1996-05-23 1997-11-27 Medical Research Council Selection d'agents pour le traitement de la maladie d'alzheimer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044669A1 (fr) * 1996-05-23 1997-11-27 Medical Research Council Selection d'agents pour le traitement de la maladie d'alzheimer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.M. WISCHIK ET AL.: "selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.", PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 11213 - 11218, XP002067057 *
M. PÉREZ ET AL.: "Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction.", J. NEUROCHEM., vol. 67, no. 3, 1996, pages 1183 - 1190, XP002066480 *

Also Published As

Publication number Publication date
JP2001506617A (ja) 2001-05-22
WO1998025640A2 (fr) 1998-06-18
EP1019069A2 (fr) 2000-07-19
AU5757598A (en) 1998-07-03
US20020197737A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
WO1999014346A3 (fr) THERAPIES GENIQUES A BASE D'ARNm SENS
WO2003012030A3 (fr) Inhibiteurs et activateurs selectifs d'isoformes de phosphodiesterases nucleotidiques cycliques pde3
BG103232A (en) Heterocyclic esters and amides
TWI224595B (en) New benzazepine derivatives, drugs containing these and use of the same for producing drugs
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
WO1990004387A3 (fr) Composition de traitement de symptomes relatifs au manque de tabac
WO2002069900A3 (fr) Procede de traitement de troubles proliferatifs d'origine genetique par des inhibiteurs de hsp90
WO2002044156A3 (fr) Composes chimiques
CA2000786A1 (fr) 3-piperidinyl-1,2-benzisoxazoles
WO2001049703A3 (fr) Sapogenines substituees et leur utilisation
HUP0203064A2 (en) Granules based on starch and lactose
CA2296769A1 (fr) Facteur modifie affectant le tissu dorsal et composition a base de ce facteur
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
CA2200195A1 (fr) Utilisation d'inhibiteurs d'aromatase pour la production d'un medicament destine alu traitement d'une deficience relative d'androgene chez l'homme
WO2001090389A3 (fr) Production de proteines du type soie chez les plantes
HUP0200399A3 (en) Macromolecular photocrosslinkers, their use, process for preparation of crosslinked structure from composition containing the same and ophthalmic composition containing the same
WO1997020933A3 (fr) VARIANTES MUTATIONNELLES DE PROTEINES DE GENES Ob CHEZ LES MAMMIFERES
WO2002070464A3 (fr) Nouvelles hydrazones
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
WO1998025640A3 (fr) Nouveaux procedes pour tester des inhibiteurs de filaments helicoidaux apparies et leur utilisation dans le traitement de la maladie d'alzheimer
WO2000040232A3 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires
CA2251132A1 (fr) Utilisation de derives phosphonamidoalkyles de cyclopentane/ene en tant qu'agents therapeutiques
EP0916670A3 (fr) Pyrrolo-(3,2-b)pyridines et leur utilisation comme 5-HT1F agonistes
HK1016601A1 (en) Furan-and thiophenecarbothioamide derivatives, their preparation and their use as inhibitors of the replication of hiv-1 and hiv-1 mutants
WO2001059120A3 (fr) Molecules de type il-17 et utilisation de ces dernieres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 526245

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997953806

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09319812

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997953806

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997953806

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载